This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

T +34 (+34) 917 328 000 (Ext )
lpazares@ext.cnio.es
Staff Scientists
- María Teresa Agullo
- Irene Ferrer
- Itziar Otano
- Beatriz Soldevilla
Clinical Investigator
- Rocio García
- María del Carmen Riesco
- José Luis Solórzano
- Jon Zugazagoitia
Post-Doctoral Fellows
- María Cristina Cirauqui
- Juan Manuel Coya
- Gorka Ruiz de Garibay
Graduate Students
- Carlos Carretero
- Santiago García
- Alberto Lens
- Ángel Núñez
- Javier Ramos
- Beatriz Rubio
- Alba Santos Ramos
- Patricia Yagüe
Technicians
- Patricia Cozar
- Laura García
- Beatriz Gil
- Patricia Llamas
- Alicia Luengo
- Patricia Plaza
- Aranzazu Rosado
- Rocío Suárez
Lung cancer continues to be the most frequent cause of cancer-related deaths worldwide. Our Unit focuses on the study of lung cancer, from fundamental research proposals to other more clinically oriented ones, always aiming to solve the problems of lung cancer patients. We are particularly interested in 2 research areas: (i) the identification of new molecular biomarkers for diagnostic, prognostic and predictive purposes; and (ii) the development of novel treatment strategies, including targeted therapies and immunotherapeutics. For example, we have contributed to elucidating the molecular determinants of EGFR or FGFR oncogenicity and have discovered biomarkers that may guide the efficacy of inhibitors of those receptors in lung cancer. We have developed an extensive platform of patient-derived xenografts of non-small-cell lung cancers to test new therapeutic strategies. Finally, our Unit has extensive experience in taking new drugs to the clinic, as well as in conducting practice-changing phase II/III trials in the fields of personalised cancer care and immuno-oncology.
Publications
- (2020). Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers 12, E2394. CNIO Publication.
Open Access
- (2020). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clin Cancer Res 26, 902-909. CNIO Publication.
- (2020). VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).. Cancer Med 9, 1008-1016. CNIO Publication.
Open Access
- (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-ß and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial.. J Thorac Oncol 15, 1210-1222. CNIO Publication.
- (2020). Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.. Lancet Oncol 21, 645-654. CNIO Publication.
- (2020). Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.. Ann Oncol (in press). CNIO Publication.
- (2020). Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab. Clin Lung Cancer 21, 75-85. CNIO Publication.
- (2020). Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol 38, 271-280. CNIO Publication.
- (2020). Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention.. MOLECULAR & CELLULAR ONCOLOGY 7, 1709389. CNIO Publication.
- (2020). Challenges and Opportunities of cfDNA Analysis Implementation in Clinical Practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol 151, 102978. CNIO Publication.
- (2020). Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma. Translational oncology (in press). CNIO Publication.
Open Access
- (2020). Prolonged Lenalidomide Maintenance Therapy Improves the Depth of Response in Multiple Myeloma. Blood Adv 4, 2163-2171. CNIO Publication.
- (2020). A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. Front Oncol 10, 578756. CNIO Publication.
- (2020). Update of the Recommendations for the Determination of Biomarkers in Colorectal Carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol (in press). CNIO Publication.
- (2020). The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer.. Expert Opin Drug Saf 19, 233-242. CNIO Publication.
- (2020). High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. Eur J Cancer 14, 193-198. CNIO Publication.
- (2020). Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival. Int J Cancer (in press). CNIO Publication.
- (2020). Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. J Thorac Oncol (in press). CNIO Publication.
- (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.. Lancet Oncol 21, 271-282. CNIO Publication.
- (2020). Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.. J Clin Invest 130, 612-624. CNIO Publication.
- (2020). A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol (in press). CNIO Publication.
- (2020). FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine 53, 102683. CNIO Publication.
Open Access
- (2020). Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. Br J Cancer 123, 793-802. CNIO Publication.
- (2019). Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.. J Clin Oncol 37, 2571-2580. CNIO Publication.
Open Access
- (2019). Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer-J Iaslc 134, 72-78. CNIO Publication.
- (2019). Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC – Update from PACIFIC.. J Thorac Oncol (in press). CNIO Publication.
- (2019). FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer-J Iaslc 131, 112-121. CNIO Publication.
- (2019). Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.. Cells 8, E806. CNIO Publication.
Open Access
- (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929-1939. CNIO Publication.
- (2019). Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20, 1655-1669. CNIO Publication.
- (2019). Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br J Cancer 121, 537-544. CNIO Publication.
- (2019). A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One 14, e0221994. CNIO Publication.
Open Access
- (2019). Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study.. Ann Oncol 30, 124-131. CNIO Publication.
- (2019). First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.. Lung Cancer-J Iaslc 133, 10-19. CNIO Publication.
- (2019). First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.. Lung Cancer-J Iaslc 134, 245-253. CNIO Publication.
- (2019). Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.. Clin Lung Cancer 20, e601-e608. CNIO Publication.
- (2019). Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.. Clin Transl Oncol 14, 2120-2132. CNIO Publication.
- (2019). Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Ann Oncol 30, 439-446. CNIO Publication.
- (2019). Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol 30, 124-131. CNIO Publication.
- (2019). Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol 30, 290-296. CNIO Publication.
- (2019). FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. J Thorac Oncol 14, 641-655. CNIO Publication.
- (2019). HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opin Inv Drug 28, 29-38. CNIO Publication.
- (2019). Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Ther Adv Endocrinol Metab 10, 1-12. CNIO Publication.
- (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol 30, 161-165. CNIO Publication.
- (2019). Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer 108, 120-128. CNIO Publication.
- (2019). First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin 145, 1569-1579. CNIO Publication.
- (2019). Necitumumab for the treatment of advanced non-small-cell lung cancer. Future Oncol 15, 705-716. CNIO Publication.
- (2019). Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future Oncol 15, 1363-1383. CNIO Publication.
- (2019). SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clin Transl Oncol 21, 55-63. CNIO Publication.
- (2019). Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer-J Iaslc 132, 126-131. CNIO Publication.
- (2019). From the pathophysiology of the human lung alveolus to epigenetic editing: Congress 2018 highlights from ERS Assembly 3 “Basic and Translational Science. ERJ Open Res 5, pii: 00194. CNIO Publication.
- (2019). TGFß receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemoth Pharm 83, 975-991. CNIO Publication.
- (2019). YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Am J Resp Crit Care 200, 888-899. CNIO Publication.
- (2019). A patent review of FGFR4 selective inhibition in cancer (2007-2018). Expert Opin Ther Pat 29, 429-438. CNIO Publication.
- (2019). Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology 108, 54-62. CNIO Publication.
- (2019). Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. Oncologist 24, 1375-1383. CNIO Publication.
- (2019). Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.. New Engl J Med 381, 2020-2031. CNIO Publication.
- (2019). Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients. Cancer Chemoth Pharm (in press). CNIO Publication.
- (2019). Antitumor Activity of an Engineered Decoy Receptor Targeting CLCF1-CNTFR Signaling in Lung Adenocarcinoma. Nat Med 25, 1783-1795. CNIO Publication.
- (2018). Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. New Engl J Med 378, 2093-2104. CNIO Publication.
- (2018). Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New Engl J Med 379, 2342-2350. CNIO Publication.
- (2018). Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol 29, 1701-1709. CNIO Publication.
Open Access
- (2018). Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol 29, 119-126. CNIO Publication.
- (2018). Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol 29, 602-609. CNIO Publication.
- (2018). Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29, i10-i19. CNIO Publication.
- (2018). Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J 51, 1702431. CNIO Publication.
- (2018). Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol 13, 165-183. CNIO Publication.
- (2018). bemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.. Clin Cancer Res 24, 5543-5551. CNIO Publication.
- (2018). MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. J Exp Clin Cancer Res 37, 195. CNIO Publication.
Open Access
- (2018). Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer 119, 1208-1214. CNIO Publication.
- (2018). Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr-Relat Cancer 25, 309-322. CNIO Publication.
- (2018). Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist 23, 422-432. CNIO Publication.
- (2018). Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. Oncotarget 9, 19945-19960. CNIO Publication.
Open Access
- (2018). ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Cancer 124, 4667-4675. CNIO Publication.
- (2018). Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs 78, 893-911. CNIO Publication.
- (2018). Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer 19, 130-138. CNIO Publication.
- (2018). Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer 19, 331-339. CNIO Publication.
- (2018). Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.. Clin Lung Cancer (in press). CNIO Publication.
- (2018). Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer 19, 213-220. CNIO Publication.
- (2018). Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer 19, e465-e479. CNIO Publication.
- (2018). Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments. Clin Lung Cancer 19, 65-73. CNIO Publication.
- (2018). The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Sci Rep 8, 2394. CNIO Publication.
Open Access
- (2018). Aligning digital CD8+ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. Histopathology 72, 270-284. CNIO Publication.
- (2018). Necitumumab: a new option for first-line treatment of squamous cell lung cancer. Expert Opin Drug Metab Toxicol 14, 765-772. CNIO Publication.
- (2018). Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. Thromb Res 167, 50-56. CNIO Publication.
- (2018). Second-line treatment options in non-small-cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Clin Lung Cancer 19, 301-314. CNIO Publication.
- (2018). Early career members at the ERS lung science conference: cell-matrix interactions in lung disease and regeneration: early career forum. Breathe 14, e78-e83. CNIO Publication.
Open Access
- (2018). Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treat Rev 70, 209-222. CNIO Publication.
- (2018). Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. New Engl J Med 379, 2342-2350. CNIO Publication.
- (2018). Abemaciclib in combination with single-agent options in patients with stage IV non-small cell lung cancer: a phase Ib study. Clin Cancer Res 24, 5543-5551. CNIO Publication.
- (2018). KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer-J Iaslc 124, 53-64. CNIO Publication.
- (2017). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New Engl J Med 377, 1919-1929. CNIO Publication.
- (2017). First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.. New Engl J Med 376, 2415-2426. CNIO Publication.
- (2017). Lung cancer: current therapies and new targeted treatments.. Lancet 389, 299-311. CNIO Publication.
- (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.. Lancet 389, 917-929. CNIO Publication.
- (2017). Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 35, 2781-2789. CNIO Publication.
- (2017). Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol 35, 412-420. CNIO Publication.
- (2017). Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.. Ann Oncol 28, 270-277. CNIO Publication.
- (2017). Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer.. Ann Oncol (in press). CNIO Publication.
- (2017). Biological therapies in nonsmall cell lung cancer.. Eur Respir J 49, 1601520. CNIO Publication.
- (2017). Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.. Expert Opin Inv Drug 26, 1295-1305. CNIO Publication.
- (2017). A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Clin Lung Cancer 18, 615-625. CNIO Publication.
- (2017). Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. Clin Lung Cancer 18, 667-674. CNIO Publication.
- (2017). Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. Clin Lung Cancer 18, 68-72. CNIO Publication.
- (2017). Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.. Lung Cancer-J Iaslc 104, 45-51. CNIO Publication.
- (2017). A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer-J Iaslc 108, 212-216. CNIO Publication.
- (2017). Prognostic relevance of Src activation in stage II-III colon cancer.. Hum Pathol 67, 119-125. CNIO Publication.
- (2017). Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.. ESMO OPEN 2, e000261. CNIO Publication.
- (2016). The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.. JOURNAL OF GYNECOLOGIC ONCOLOGY 27, E7. CNIO Publication.
- (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.. Lancet Oncol 17, 577-589. CNIO Publication.
- (2016). Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat.. Lancet Oncol 17, 1622-1623. CNIO Publication.
- (2016). Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.. Ann Oncol 27, 1573-1579. CNIO Publication.
- (2016). Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.. Ann Oncol 27, 1363. CNIO Publication.
- (2016). Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. Oncotarget 9, 4395-4410. CNIO Publication.
Open Access
- (2016). Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. Oncotarget 7, 52849-52861. CNIO Publication.
Open Access
- (2016). Current Challenges in Cancer Treatment.. Clin Ther 38, 1551-1566. CNIO Publication.
- (2016). Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.. Dis Markers 2016, 2138627. CNIO Publication.
- (2016). Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.. Dis Markers 2016, 9214056. CNIO Publication.